Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes drug tested in kids: how long does it stay in the body?

NCT ID NCT06362265

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how a new medicine, LY3209590, is processed in the bodies of 15 children with type 2 diabetes. Each child received one dose, and researchers measured the drug levels in their blood over time. The goal was to understand how the drug is absorbed and removed, not to treat the disease. The study lasted about 100 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

15 people

The number who actually took part.

Started

Oct 2024

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with Type 2 Diabetes Mellitus (T2DM) for at least 3 months * Have Glycated hemoglobin (HbA1c) level of 6.5 percent (%) to 9.5% at screening * Have a body mass index equal to or less than 45.0 kilograms per square meter (kg/m²) * Participants are insulin naïve or have been without insulin treatment for at least 3 months prior to screening Exclusion Criteria: * Have had a severe hypoglycemia in the past 6 months * Have a history of renal impairment * Have had a blood transfusion or severe blood loss within last 90 days * Have had a significant weight gain or loss of approximately 6% or more within 3 months prior to screening. * Have a history of an active or untreated malignancy * Are receiving or received systemic glucocorticoid therapy * Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus

Contacts and locations

Locations

  • Centricity Research Columbus Endocrinology

    Columbus, Georgia, 31904, United States

  • Children's Healthcare of Atlanta - Center for Advanced Pediatrics

    Atlanta, Georgia, 30329, United States

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229-3039, United States

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • Joslin Diabetes Center

    Boston, Massachusetts, 02215, United States

  • Lifedoc Research - Lenox Park Drive

    Memphis, Tennessee, 38115, United States

  • NYU Langone

    New York, New York, 10016, United States

  • UBMD Pediatrics

    Buffalo, New York, 14203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.